Arovella receives R&D tax rebate of $4.03 million
Filed with ASX ·
6ix is reading this filing.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Second Clinical Batch Released for Immediate Patient Use
- The path to first patient dosing
- Clinical manufacturing batch released, first site activated
- Arovella Appoints Acting CEO
- Board Refresh and CEO Resignation
Later from Arovella Therapeutics
All Arovella Therapeutics news releasesFollow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics